

STROBE Statement—Checklist of items that should be included in reports of *case-control studies*

	Item No	Recommendation	
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	yes
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	yes
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	yes
Objectives	3	State specific objectives, including any prespecified hypotheses	yes
Methods			
Study design	4	Present key elements of study design early in the paper	yes
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	yes
Participants	6	(a) Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	yes
		(b) For matched studies, give matching criteria and the number of controls per case	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	yes
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	yes
Bias	9	Describe any efforts to address potential sources of bias	yes
Study size	10	Explain how the study size was arrived at	yes
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	yes
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	yes
		(b) Describe any methods used to examine subgroups and interactions	yes
		(c) Explain how missing data were addressed	yes
		(d) If applicable, explain how matching of cases and controls was addressed	yes
		(e) Describe any sensitivity analyses	NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	yes
		(b) Give reasons for non-participation at each stage	yes
		(c) Consider use of a flow diagram	yes
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	yes
		(b) Indicate number of participants with missing data for each variable of interest	yes
Outcome data	15*	Report numbers in each exposure category, or summary measures of exposure	yes
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	yes
		(b) Report category boundaries when continuous variables were categorized	yes
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	yes

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
Discussion			
Key results	18	Summarise key results with reference to study objectives	yes
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	yes
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	yes
Generalisability	21	Discuss the generalisability (external validity) of the study results	yes
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	yes

*Give information separately for cases and controls.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.